TY  - JOUR

T1  - Adjusting for the Confounding Effects of Treatment Switching—The BREAK‐3 Trial: Dabrafenib Versus Dacarbazine

JO  - The Oncologist

PY  - 2015/06/03

AU  - Latimer NR

AU  - Abrams KR

AU  - Amonkar MM

AU  - Stapelkamp C

AU  - Swann RS

ED  - 

DO  - DOI: 10.1634/theoncologist.2014-0429

PB  - Wiley

VL  - 20

IS  - 7

SP  - 798

EP  - 805

Y2  - 2024/12/22

ER  -